Schedule a Meeting
Download Brochure
Table of Content
April 2025
Principal Consultant
Reviewed By
The global myasthenia gravis market size is calculated at US$ 1.45 in 2024, grew to US$ 1.56 billion in 2025, and is projected to reach around US$ 2.95 billion by 2034. The market is expanding at a CAGR of 7.35% between 2025 and 2034. The rising geriatric population is driving the myasthenia gravis market.
A persistent neuromuscular condition called myasthenia gravis results in voluntary muscle weakening. Being an autoimmune illness, myasthenia gravis occurs when the body's defense mechanism unintentionally targets healthy cells or proteins that are essential for regular operation. The incidence and prevalence of myasthenia gravis (MG) have increased dramatically in recent years on a global scale. Any age can be affected by myasthenia gravis. However, women under 40 and men over 60 are more likely to have it. Preventing a deteriorating quality of life due to myasthenia gravis illness is the primary factor driving the worldwide market for myasthenia gravis disease. Growing R&D efforts for innovative treatments are also contributing to the market's expansion.
A more comprehensive method of MG evaluation is now possible due to recent AI-based neurology models. The time needed to score the neuromuscular tests was greatly decreased by the AI-powered approach. By breaking apart the telemedicine films and examining each clip, the AI technology automates the time-consuming manual grading of MG-CE tests. The AI system achieved a 97% success rate in identifying gaze direction frames from the segmented films and is very proficient in identifying and scoring tests pertaining to arm strength, diplopia, and ptosis.
Rising Cases of Myasthenia
The need for efficient treatment alternatives is being greatly fueled by the rising incidence and prevalence of myasthenia gravis worldwide. According to a National Institutes of Health study, the disease's incidence ranges from 4.1 to 30 cases per million person-years, while its prevalence rate is between 150 and 200 cases per million. As more medical professionals become aware of the disease's symptoms and work to diagnose those who are afflicted, these numbers are predicted to rise. In the end, this increased knowledge contributes to market growth in the myasthenia gravis environment by facilitating early diagnosis and treatment and highlighting the urgent need for viable therapeutic choices.
High Cost of Treatment
The market for managing Generalized Myasthenia Gravis (GMG) is beset by issues such as high medical service costs, including immunosuppressive drugs and other biological therapies, and the difficulty in gaining access to specialized medical facilities and neurology specialists as a result of the disease's ongoing development. In addition to being a challenging illness to treat on its own, it also has a significant financial impact on the patient and the healthcare systems.
Technological Advancements
Technology, such as wearables, digital health solutions, and telemedicine, is changing the way myasthenia gravis is managed. As a result of these technological advancements, the market is growing through better patient interaction, personalized treatment, and remote monitoring. Investments in precision medical techniques, biomarkers, and innovative therapies will shape the market's future. The development of new diagnostic tools and therapies helps with the early detection and treatment of the condition, which improves patient outcomes and propels the market growth.
By treatment type, the immunosuppressants segment led the myasthenia gravis market in 2024. The cornerstone of therapy for MG is immunosuppression. With the best effectiveness data to date, azathioprine is the most often used steroid-sparing immunosuppressant in MG. For many MG patients, long-term stability can be achieved by chronic immunosuppressive treatment. In the near future, newly developed innovative therapeutics with more focused immunosuppression may provide choices for patients who remain resistant or who cannot tolerate the available drug options because of adverse events.
By treatment type, the monoclonal antibodies segment is expected to be the fastest-growing in the myasthenia gravis market during the forecast period. It has recently been demonstrated that monoclonal antibodies can effectively cure a number of illnesses. The number of possible therapeutic options has greatly increased due to the significant advancements in monoclonal antibody technology that enable targeted modification of biological processes. Monoclonal antibody treatments for MG focus on the effector mechanisms of complement inhibition and FcRn inhibition, which lower antibody levels. The number of possible therapeutic options has greatly increased due to the significant advancements in monoclonal antibody technology that enable targeted modification of biological processes.
By distribution channel, the hospital pharmacies segment held the largest share of the myasthenia gravis market in 2024. This is explained by the availability of a sizable patient base and the strong need for cutting-edge equipment for the treatment of MG in hospital settings. The availability of a wide range of treatment choices in such institutions has led to a rise in patient visits for MG diagnosis and treatment. Furthermore, the growing investment in cutting-edge healthcare infrastructures is one of the main factors behind its high share.
By distribution channel, the online pharmacies segment is expected to grow at the fastest rate in the myasthenia gravis market during 2025-2034. Patients' preference for online pharmacies has changed as a result of shifting regulations for online prescription medicine sales in developed countries combined with the presence of major e-pharmacy companies in those countries. Due to customers' growing preference for online buying over conventional ways of purchase, e-commerce, or electronic commerce, has emerged as a crucial tool for both small and large firms worldwide.
By symptoms, the muscle weakness segment held the major share of the myasthenia gravis market in 2024. MG occurs when there is a breakdown in the nerve-muscle communication system. Muscle weakness results from this impairment because it stops essential muscle contractions from taking place. Along with other specialized electrodiagnostic tests, such as electromyography (EMG), which gauges electrical activity or muscle response to nerve stimulation, there are tests for eye muscle weakness. Patients with significantly weak muscles or MG that is deemed brittle may be candidates for surgical delivery if their MG condition is inadequately managed.
By symptoms, the difficulty in breathing segment was estimated to grow at a significant rate in the myasthenia gravis market during the predicted time frame. The most severe MG symptom is weakness of the respiratory muscles, and 10–15% of individuals will at some point in their lives have an MG crisis requiring mechanical ventilatory assistance. Patients with MG who have respiratory muscle weakness require long-term active immunosuppressive medication therapy as well as routine follow-up with specialists. Respiratory function-affecting comorbidities require attention and the best care possible. An MG crisis and MG exacerbations can be caused by respiratory tract infections.
By age group, the adult segment dominated the myasthenia gravis market in 2024. Although it is more frequent in adults than in children, myasthenia gravis can be diagnosed in anybody. All racial and ethnic groups are affected by myasthenia gravis, which can affect both males and women. It can happen at any age, including youth, although it most frequently affects older males (over 60) and young adult women (under 40). 85–90% of MG forms in the U.S. and Europe are adult-onset. When an adult's anti-acetylcholine receptor (AchR) antibody test results are positive, the FDA has authorized eculizumab (Soliris).
By age group, the geriatric segment is expected to grow at a lucrative rate in the myasthenia gravis market during the forecast period. At a primarily female dominance, the first frequency peak occurred between the ages of 20 and 40; at a male dominance, the second frequency peak occurred between the ages of 55 and 75. Due to the severity of the illness presentation and the need to pay attention to the adverse effects of these medications in the senior age group, treatment for older patients has mostly involved drug-induced immunosuppression.
North America dominated the myasthenia gravis market in 2024 both in terms of revenue and market share and is anticipated to keep this advantage for the duration of the projection. This dominance is a result of the increasing incidence and prevalence of myasthenia gravis, especially in the United States, where growing awareness and improved treatment options have further stimulated market expansion. The region's established healthcare system and increased awareness of autoimmune diseases further support the market's ongoing growth.
Findings indicate that a large number of Americans who are currently living with MG reported having uncontrolled conditions. Approximately 132,400 individuals in the U.S. suffer from myasthenia gravis, according to the National Institute of Neurological Disorders and Stroke. One myasthenic crisis occurs in around 15 to 20 percent of individuals with myasthenia gravis.
To lessen the significant burden that people with myasthenia gravis (MG), a rare neuromuscular illness, face, Canadians must have access to innovative care. The approval of new medicines for people with refractory MG in Canada for the first time in more than 30 years gives hope to those for whom existing treatments are not working. In reaction to the ongoing care gap, members of the MG community, including medical professionals from all around Canada, have spoken out about how critical it is to have prompt access to cutting-edge illness treatment choices.
Asia Pacific is estimated to host the fastest-growing myasthenia gravis market during the forecast period. Because of rising MG awareness, better healthcare infrastructure, and rising healthcare investments in nations like China and Japan, the Asia-Pacific market is developing quickly. The market has a lot of room to develop, especially as biologics become more widely available and reasonably priced in this area. It is anticipated that rising healthcare costs in nations like China, Japan, and India would fuel more expansion in MG therapies. The two biggest markets in the area are China and Japan, with Japan having a more developed MG treatment market. China's enormous population and rising healthcare spending are also contributing factors to its rise.
One of the uncommon chronic autoimmune diseases that has been added to China's First List of uncommon Diseases is myasthenia gravis (MG). By 2025, there will be 1.5 million myasthenia gravis patients worldwide, with around 217,000 of those people in China, according to the Frost & Sullivan analysis. A well-known biopharmaceutical business in China, RemeGen is dedicated to meeting the unmet therapeutic requirements of patients with life-threatening conditions. RemeGen maintains offices and research labs in both China and the U.S.
Researching and promoting high-quality medical care for MG patients in Japan has been the main goal of the Japanese Myasthenia Gravis Registry (JAMG-R). The Japanese MG guidelines' fundamental policies seem to be progressively gaining traction. As the fundamental principles of the MG recommendations are embraced more broadly and over time, the circumstances of MG patients in Japan are progressively getting better.
Europe is expected to be significantly growing in the myasthenia gravis market during the forecast period. The result of effective pharmacy management components. Germany, the UK, and France are focusing their efforts on developing innovative rare disease treatments with financial support from their public health systems. New immunotherapies and biologics are being adopted quickly in the region due to the EMA's strict drug approval process and growing cooperation between biotech companies and research institutions. Patient-centric practices and improving clinical outcomes are becoming more and more important.
In the UK, around 15 out of every 100,000 persons suffer from this rare illness. The government is working very hard to control MG. For instance, rozanolixizumab, also known as Rystiggo, was licensed by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat individuals with generalized myasthenia gravis.
In October 2024, according to Kimberly Moran, SVP & Head of U.S. Rare Diseases at UCB, we see the person, not just the disease, and the UCB Myasthenia Gravis Scholarship is one way we help those affected by a rare disease live the life they desire, even if that includes pursuing educational ambitions. The tenacity of the myasthenia gravis community continues to inspire us, and we are motivated to act to address their unmet needs.
By Treatment Type
By Distribution Channel
By Symptoms
By Age Group
By Region
April 2025
April 2025
April 2025
April 2025